2.1. Demographic Characteristics
obesity
OBESITY, DISEASE
Fifty patients were enrolled in this study; however, only twenty-nine completed the intervention. Three of the enrolled patients were excluded because they did not meet the inclusion criteria, and five of them resigned due to the COVID pandemic. During the follow-up, we lost two patients from the VitD group and five patients from the PL group because they did not show up on the second visit for functional tests due to problems with transport. Six patients from the VitD group resigned from this study due to unforeseen circumstances. All patients who completed the intervention were Caucasian and met the inclusion criteria. No statistically significant differences were observed between the groups. The average age was 63 ± 9 years old in the VitD group and 66 ± 6 years in the PL group. The mean height and body mass were respectively 169 ± 12 cm and 78 ± 11 kg in the VitD group, and 174 ± 8 cm and 80 ± 20 kg in the PL group. There were six men (M) and seven women (W) in the VitD group and thirteen M and three W in the PL group. The time from DBS implantation varied from three to five years in both groups. In the off-medication condition, mean motor improvement after DBS stimulation, as assessed with UPDRS part III, was 45% (range 35–60%). The mean L-dopa-equivalent medication dosage reduction was 35%. Stimulation parameters were: monopolar stimulation in all patients, frequency 130 Hz, pulse duration 60 us, current 1.8–3.8 mA (in twenty patients with constant current stimulators), and voltage 1.9–4.2 V (in nine patients with constant voltage stimulators). Hoehn and Yahr’s (H&Y) scores in both groups were 2.5. Duration of the disease varies from 8 to 13 years in the VitD and PL groups. In the VitD group, there were three patients with normal weight, eight who were overweight, and two with obesity. In the PL group, there were six patients with normal weight, eight who were overweight, and two with obesity. The characteristics of patients are shown in 